Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8Sarcoma 5Neoplasms 5Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1MSI-H or dMMR Advanced Solid Tumors 1Lung Neoplasms 1Leiomyosarcoma 1Gynecological Cancer 1Gastrointestinal Stromal Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Fallopian Tube Neoplasms 1Extensive Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gynecological Cancer × anlotinib × Clear all
NCT04236362 2021-01-12

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
90 enrolled

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡